Literature DB >> 26449464

MicroRNA-139-5p acts as a tumor suppressor by targeting ELTD1 and regulating cell cycle in glioblastoma multiforme.

Shouping Dai1, Xianjun Wang2, Xiao Li3, Yuandong Cao4.   

Abstract

MicroRNA-139-5p was identified to be significantly down-regulated in glioblastoma multiform (GBM) by miRNA array. In this report we aimed to clarify its biological function, molecular mechanisms and direct target gene in GBM. Twelve patients with GBM were analyzed for the expression of miR-139-5p by quantitative RT-PCR. miR-139-5p overexpression was established by transfecting miR-139-5p-mimic into U87MG and T98G cells, and its effects on cell proliferation were studied using MTT assay and colony formation assays. We concluded that ectopic expression of miR-139-5p in GBM cell lines significantly suppressed cell proliferation and inducing apoptosis. Bioinformatics coupled with luciferase and western blot assays also revealed that miR-139-5p suppresses glioma cell proliferation by targeting ELTD1 and regulating cell cycle.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell cycle; ELTD1; Glioma; miR-139-5p

Mesh:

Substances:

Year:  2015        PMID: 26449464     DOI: 10.1016/j.bbrc.2015.10.006

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  miR-206 inhibits renal cell cancer growth by targeting GAK.

Authors:  Chao Wei; Shen Wang; Zhang-Qun Ye; Zhi-Qiang Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-12-07

2.  ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.

Authors:  Jadith Ziegler; Richard Pody; Patricia Coutinho de Souza; Blake Evans; Debra Saunders; Nataliya Smith; Samantha Mallory; Charity Njoku; Yunzhou Dong; Hong Chen; Jiali Dong; Megan Lerner; Osamah Mian; Sai Tummala; James Battiste; Kar-Ming Fung; Jonathan D Wren; Rheal A Towner
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

Review 3.  The Emerging Role of Adhesion GPCRs in Cancer.

Authors:  Abanoub A Gad; Nariman Balenga
Journal:  ACS Pharmacol Transl Sci       Date:  2020-01-13

Review 4.  Adhesion GPCRs in Tumorigenesis.

Authors:  Gabriela Aust; Dan Zhu; Erwin G Van Meir; Lei Xu
Journal:  Handb Exp Pharmacol       Date:  2016

5.  MicroRNA-139 inhibits the proliferation, migration and invasion of gastric cancer cells by directly targeting ρ-associated protein kinase 1.

Authors:  Xuechun Yu; Chaojian Ma; Ling Fu; Jingwu Dong; Jie Ying
Journal:  Oncol Lett       Date:  2018-02-13       Impact factor: 2.967

6.  MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma.

Authors:  Jianan Chen; Yan Yu; Xiaolong Chen; Yuting He; Qiuyue Hu; Hongqiang Li; Qicai Han; Fang Ren; Juan Li; Chao Li; Jie Bao; Zhigang Ren; Zhenfeng Duan; Guangying Cui; Ranran Sun
Journal:  Cell Prolif       Date:  2018-08-13       Impact factor: 6.831

7.  MiR-139-5p inhibits the tumorigenesis and progression of oral squamous carcinoma cells by targeting HOXA9.

Authors:  Kai Wang; Jun Jin; Tengxiao Ma; Hongfeng Zhai
Journal:  J Cell Mol Med       Date:  2017-08-05       Impact factor: 5.310

8.  miR-195-5p Suppresses the Proliferation, Migration, and Invasion of Oral Squamous Cell Carcinoma by Targeting TRIM14.

Authors:  Tong Wang; Yipeng Ren; Ruixun Liu; Juntao Ma; Yueyi Shi; Lei Zhang; Rongfa Bu
Journal:  Biomed Res Int       Date:  2017-10-24       Impact factor: 3.411

Review 9.  ELTD1-An Emerging Silent Actor in Cancer Drama Play.

Authors:  Ani-Simona Sevastre; Iuliana M Buzatu; Carina Baloi; Alexandru Oprita; Alexandra Dragoi; Ligia G Tataranu; Oana Alexandru; Stefania Tudorache; Anica Dricu
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

Review 10.  MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.

Authors:  Amanda Shea; Varsha Harish; Zainab Afzal; Juliet Chijioke; Habib Kedir; Shahnoza Dusmatova; Arpita Roy; Malathi Ramalinga; Brent Harris; Jan Blancato; Mukesh Verma; Deepak Kumar
Journal:  Cancer Med       Date:  2016-06-10       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.